Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- ACCEL Lite: Risk vs. Benefit in Chronic Total Occlusion RevascularizationIn this interview, Drs. Anthony N. DeMaria and Lindsey Cilia examine “Risk versus Benefit in Chronic Total Occlusion Revascularization.
- ACC Launches HCM Digital RegistryWith the launch of the new CONNECT-HCM Registry, the ACC aims to accelerate insights into hypertrophic cardiomyopathy (HCM) and expand equitable access to treatment.
- Self-Service BP Kiosks May Help Improve Hypertensive Health NationwideAlthough self-reported hypertension diagnoses and blood pressure (BP) readings from health kiosks in retail stores tend to be higher than those obtained from national surveys, self-service kiosks can supplement efforts to reduce the burden of hypertension on a national level...
- CPAP May Improve CV Outcomes in High-Risk OSAContinuous positive airway pressure (CPAP) improves cardiovascular outcomes in high-risk obstructive sleep apnea (OSA) but may increase cardiovascular risk in low-risk OSA, according to a multi-trial analysis published Aug. 5 in EHJ.
- FLAVOUR: Comparable Outcomes With FFR and IVUS For Intermediate Coronary StenosisLong-term outcomes were comparable with fractional flow reserve (FFR)-guided and IVUS-guided treatment in patients with intermediate coronary stenosis, according to an extended follow-up of the FLAVOUR trial published in JACC.